{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:59:54Z","timestamp":1790085594181,"version":"4.0.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2022R1A5A2027161"],"award-info":[{"award-number":["NRF-2022R1A5A2027161"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2026-25490305"],"award-info":[{"award-number":["RS-2026-25490305"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.biopha.2026.119842","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:25:39Z","timestamp":1786541139000},"page":"119842","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["MHY5535, a novel PPAR\u03b1 antagonist, sensitizes ovarian cancer stem cells to chemotherapy by disrupting fatty acid oxidation-dependent mitochondrial metabolism"],"prefix":"10.1016","volume":"203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7786-5980","authenticated-orcid":false,"given":"Min Joo","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Gyun","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seo Yul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Jin","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Jang","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae Young","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Ryong","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4323-4790","authenticated-orcid":false,"given":"Jae Ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2026.119842_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"16","key":"10.1016\/j.biopha.2026.119842_bib2","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1002\/cam4.2560","article-title":"Ovarian cancer: Current status and strategies for improving therapeutic outcomes","volume":"8","author":"Chandra","year":"2019","journal-title":"Cancer Med."},{"issue":"3","key":"10.1016\/j.biopha.2026.119842_bib3","article-title":"Ovarian cancer-insights into platinum resistance and overcoming It","volume":"59","author":"Havasi","year":"2023","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"10.1016\/j.biopha.2026.119842_bib4","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41392-024-01851-y","article-title":"Cancer stem cells: advances in knowledge and implications for cancer therapy","volume":"9","author":"Chu","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2026.119842_bib5","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5416923","article-title":"Cancer Stem Cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment","volume":"2018","author":"Phi","year":"2018","journal-title":"Stem Cells Int."},{"issue":"1","key":"10.1016\/j.biopha.2026.119842_bib6","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41392-025-02360-2","article-title":"Cancer stem cells: landscape, challenges and emerging therapeutic innovations","volume":"10","author":"Lee","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"10","key":"10.1016\/j.biopha.2026.119842_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cells14100717","article-title":"The metabolic landscape of cancer stem cells: insights and implications for therapy","volume":"14","author":"Milella","year":"2025","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.biopha.2026.119842_bib8","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.clnu.2023.12.005","article-title":"Peroxisome proliferator-activated receptors: a key link between lipid metabolism and cancer progression","volume":"43","author":"Li","year":"2024","journal-title":"Clin. Nutr."},{"issue":"1","key":"10.1016\/j.biopha.2026.119842_bib9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1677\/jme.0.0110037","article-title":"The peroxisome proliferator-activated receptor:retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs","volume":"11","author":"Issemann","year":"1993","journal-title":"J. Mol. Endocrinol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119842_bib10","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1172\/JCI88894","article-title":"Distinct but complementary contributions of PPAR isotypes to energy homeostasis","volume":"127","author":"Dubois","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.biopha.2026.119842_bib11","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.cmet.2022.09.023","article-title":"The role of lipids in cancer progression and metastasis","volume":"34","author":"Martin-Perez","year":"2022","journal-title":"Cell. Metab."},{"key":"10.1016\/j.biopha.2026.119842_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1184794","article-title":"The role of peroxisome proliferator-activated receptors in the tumor microenvironment, tumor cell metabolism, and anticancer therapy","volume":"14","author":"Sun","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119842_bib13","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/cr.2010.13","article-title":"PPARs: diverse regulators in energy metabolism and metabolic diseases","volume":"20","author":"Wang","year":"2010","journal-title":"Cell. Res."},{"issue":"20","key":"10.1016\/j.biopha.2026.119842_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cells14201610","article-title":"The emerging role of peroxisome proliferator-activated receptors in cancer stemness","volume":"14","author":"Parejo-Alonso","year":"2025","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.biopha.2026.119842_bib15","article-title":"Understanding and targeting resistance mechanisms in cancer","volume":"4","author":"Lei","year":"2023","journal-title":"MedComm (2020)"},{"key":"10.1016\/j.biopha.2026.119842_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.960317","article-title":"Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action","volume":"12","author":"Tilsed","year":"2022","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119842_bib17","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.chembiol.2017.08.028","article-title":"Targeting Metabolism for Cancer Therapy","volume":"24","author":"Luengo","year":"2017","journal-title":"Cell. Chem. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119842_bib18","doi-asserted-by":"crossref","DOI":"10.1172\/JCI148550","article-title":"Clinical development of metabolic inhibitors for oncology","volume":"132","author":"Lemberg","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2026.119842_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2025.103637","article-title":"OXPHOS inhibition overcomes chemoresistance in triple negative breast cancer","volume":"83","author":"Uslu","year":"2025","journal-title":"Redox Biol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119842_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010062","article-title":"The effect of oxidative phosphorylation on cancer drug resistance","volume":"15","author":"Zhao","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"5-6","key":"10.1016\/j.biopha.2026.119842_bib21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.18632\/genesandcancer.176","article-title":"Tumor metabolism regulating chemosensitivity in ovarian cancer","volume":"9","author":"Han","year":"2018","journal-title":"Genes. Cancer"},{"key":"10.1016\/j.biopha.2026.119842_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216396","article-title":"Targeting cancer metabolic pathways for improving chemotherapy and immunotherapy","volume":"575","author":"Luo","year":"2023","journal-title":"Cancer Lett."},{"issue":"23","key":"10.1016\/j.biopha.2026.119842_bib23","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Bayat Mokhtari","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2026.119842_bib24","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.2147\/CMAR.S538281","article-title":"Metabolic reprogramming shapes the progression and therapeutic landscape of ovarian cancer","volume":"17","author":"Liu","year":"2025","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.biopha.2026.119842_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jare.2026.01.047","article-title":"Metabolic vulnerabilities in ovarian cancer decoding the nexus between nutrient adaptation and therapy resistance","author":"Guo","year":"2026","journal-title":"J. Adv. Res."},{"issue":"7","key":"10.1016\/j.biopha.2026.119842_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19071907","article-title":"The involvement of PPARs in the peculiar energetic metabolism of tumor cells","volume":"19","author":"Antonosante","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2026.119842_bib27","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/1535-7163.MCT-19-0360","article-title":"Development of a novel multi-isoform ALDH inhibitor effective as an antimelanoma agent","volume":"19","author":"Dinavahi","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.biopha.2026.119842_bib28","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3892\/ijo.2017.4129","article-title":"Canonical and non-canonical WNT signaling in cancer stem cells and their niches: cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review)","volume":"51","author":"Katoh","year":"2017","journal-title":"Int. J. Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119842_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19071939","article-title":"Therapeutic opportunities of targeting histone deacetylase isoforms to eradicate cancer stem cells","volume":"19","author":"Lin","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2026.119842_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9020127","article-title":"PPARalpha-selective antagonist GW6471 inhibits cell growth in breast cancer stem cells inducing energy imbalance and metabolic stress","volume":"9","author":"Castelli","year":"2021","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/j.biopha.2026.119842_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071115","article-title":"Inhibition of PPARalpha induces cell cycle arrest and apoptosis, and synergizes with glycolysis inhibition in kidney cancer cells","volume":"8","author":"Abu Aboud","year":"2013","journal-title":"PLoS. One"},{"issue":"5","key":"10.1016\/j.biopha.2026.119842_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2024.167164","article-title":"Metabolic adaptations in cancer stem cells: a key to therapy resistance","volume":"1870","author":"Masoudi","year":"2024","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.biopha.2026.119842_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102039","article-title":"Peroxisome proliferator-activated receptors: key regulators of tumor progression and growth","volume":"47","author":"Asgharzadeh","year":"2024","journal-title":"Transl. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2026.119842_bib34","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1021\/cr2001355","article-title":"PPARs and lipid ligands in inflammation and metabolism","volume":"111","author":"Harmon","year":"2011","journal-title":"Chem. Rev."},{"issue":"24","key":"10.1016\/j.biopha.2026.119842_bib35","doi-asserted-by":"crossref","first-page":"13919","DOI":"10.1073\/pnas.241410198","article-title":"Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors","volume":"98","author":"Xu","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"28","key":"10.1016\/j.biopha.2026.119842_bib36","doi-asserted-by":"crossref","first-page":"46273","DOI":"10.18632\/oncotarget.17695","article-title":"Novel PPARalpha agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.biopha.2026.119842_bib37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12253-019-00677-2","article-title":"Inhibition of metabolic shift can decrease therapy resistance in human high-grade glioma cells","volume":"26","author":"Petovari","year":"2020","journal-title":"Pathol. Oncol. Res."},{"issue":"9","key":"10.1016\/j.biopha.2026.119842_bib38","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1136\/gutjnl-2022-328364","article-title":"Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma","volume":"72","author":"Xiong","year":"2023","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.biopha.2026.119842_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030376","article-title":"Cancer stem cells-key players in tumor relapse","volume":"13","author":"Marzagalli","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:03:38Z","timestamp":1790082218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226008784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":39,"alternative-id":["S0753332226008784"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119842","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MHY5535, a novel PPAR\u03b1 antagonist, sensitizes ovarian cancer stem cells to chemotherapy by disrupting fatty acid oxidation-dependent mitochondrial metabolism","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119842","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119842"}}